Patents

US 11505537 B2: Compositions comprising methylphenidate-prodrugs, processes of making and using the same

Granted
2022-11-22
Filed
2020-12-08 application 17115425
Type
Utility · 12 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

The present technology is directed to compositions comprising d-threo-methylphenidate conjugates and/or unconjugated methylphenidate. The present technology also relates to compositions and oral formulations comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. The present technology additionally relates to a pharmaceutical kit containing the composition comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof.

Source: PVGPATDIS, file of 2026-04-10 (ipg221122.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
KEMPHARM, INC. 57 patentsUS company or organizationIntercession City, FLKEMPHARM, INC Form D issuer EXACT high confidence: identical full name and statePVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Travis MickleKissimmee, FL83PVGPATDIS, file of 2026-04-10
Sven GuentherCoralville, IA63PVGPATDIS, file of 2026-04-10
Guochen ChiCoralville, IA41PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
C07DHeterocyclic compoundsC07D401/12PVGPATDIS, file of 2026-04-10
A61KPreparations for medical, dental or toiletry purposesA61K9/0053PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P3/04PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2026-09-11Security interest Security interest
Security interest
COMMAVE THERAPEUTICS SA signed 2026-09-10TRUIST BANK, AS ADMINISTRATIVE AGENT ATLANTA, GA75980/787PASDL, file of 2026-09-15
2026-03-26Assignment
Assignment of assignor's interest
ZEVRA THERAPEUTICS, INC. signed 2026-03-13COMMAVE THERAPEUTICS SA GENĂˆVE74195/8ECORSEXC, file of 2026-09-25
2026-03-25Name change
Change of name
KEMPHARM, INC. signed 2023-02-21ZEVRA THERAPEUTICS, INC. CELEBRATION, FL75243/8PASDL, file of 2026-10-15
2026-03-25Assignment
Assignment of assignor's interest
ZEVRA THERAPEUTICS, INC. signed 2026-03-13COMMAVE THERAPEUTICS SA GENEVA74186/531PASDL, file of 2026-10-15
2026-03-13Release of security interest
Release of security interest
ALTER DOMUS (US) LLC signed 2026-03-12ZEVRA THERAPEUTICS, INC. CELEBRATION, FL75080/907PASDL, file of 2026-10-15
2024-04-08Security interest Security interest
Security interest
ZEVRA THERAPEUTICS, INC. signed 2024-04-05ALTER DOMUS (US) LLC CHICAGO, IL67040/637PASDL, file of 2026-10-15
2021-01-14Assignment
Assignment of assignor's interest
CHI, GUOCHEN signed 2019-11-07
GUENTHER, SVEN signed 2019-11-07
MICKLE, TRAVIS signed 2019-11-11
KEMPHARM, INC. CELEBRATION, FL54920/66ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.